Obesity-related kidney disease: Beyond hypertension and insulin-resistance

Arabi, Tarek Ziad; Shafqat, Areez; Sabbah, Belal Nedal; Fawzy, Nader Ashraf; Shah, H. A.; Abdulkader, Humzah S.; Razak, Adhil; Sabbah, Ahmad Nedal; Arabi, Ziad

doi:10.3389/fendo.2022.1095211

Cited by 31 publications

(15 citation statements)

References 245 publications

(287 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For frail components, there was an interesting discovery that weight loss was associated with a higher risk of CKD. Previous studies have found that obesity was a driver of CKD progression, and the mechanisms included hemodynamic changes, in ammation, oxidative stress, and activation of the renin-angiotensinaldosterone system (RAAS) (19,20). Weight loss and RAAS blockers have a protective effect on obesityrelated CKD (21).…”

Section: Discussionmentioning

confidence: 99%

Association between frailty and chronic kidney disease: Findings from CHARLS

Yuan,

liu

2024

Preprint

View full text Add to dashboard Cite

Objectives: To investigate prevalence of frailty in CKD individuals and the relationship between frailty and CKD based on a large, nationally representative survey. Design: Retrospective cohort study. Participants: The participants were 4231 adults aged ≥50 years from the China Health and Retirement Longitudinal Study (CHARLS). Measurements: Based on the FRAIL scale, frailty and prefrailty were defined. CKD was defined as eGFR less than 60 mL/min/1.73m2, calculated according to the CKD Epidemiology Collaboration (CKD-EPI) equation, or self-reported CKD. Logistic regression models were conducted to analyze the cross-sectional relationship between frailty and CKD. Cox proportional hazards regression models were used to examine the effect of frail status and frail components on CKD. Results: We found that prevalence of frailty in CKD individuals was 13.9% while in patients without CKD was 8.4%. The prevalence of CKD in robust group was 6.0%, in prefrail group was 10.1% and in frail group was 14.0%. In frail status, after adjusted, the incidence of CKD was 1.713 (95% CI 1.109-2.646) in the frail group compared with robust group (P =0.015). While there was no statistical difference in the incidence of CKD among the prefrail group and robust group. In frail components, after adjusted, weight loss was associated with higher risk of CKD [HR (95% CI): 1.617 (1.170-2.235)]. Conclusion: The prevalence of frailty was relatively high in the population. In frail status, both prefrail and frail were associated with a higher risk of CKD. In frail components, weight loss was associated with an increase incidence of CKD. Frailty is reversible, so early identification of frailty may reduce the incidence of CKD and improve the adverse consequences associated with CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between frailty and chronic kidney disease: Findings from CHARLS

Yuan,

liu

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…46,47 However, adipocytes also possess potent endocrine functions, secreting a myriad of cytokines and adipokines that contribute to insulin resistance. 48 Dietary pattern should be adapted to appropriate calorie requirements, personal and cultural food preferences, and nutritional therapy for other medical conditions. One way to achieve this is by following plans such as the Dietary Approaches to Stop Hypertension (DASH) diet.…”

Section: Discussionmentioning

confidence: 99%

Primary health care services for obesity and hypertension in sub-urban community: focus on nutrition

et al. 2023

View full text Add to dashboard Cite

Medical nutrition therapy (MNT) is a major clinical care concept, especially for non-communicable diseases such as obesity and hypertension. Primary healthcare (PHC) centers are the first point of contact with health services and provide a point of entry for the entire health system. Research has revealed that access to primary healthcare services is associated with improved health outcomes, such as an improvement in self-rated health and a decline in all-cause mortality. However, the integration of MNT in hypertension and obesity management at PHC level is unclear. The aim of this study is to establish PHC services for obese and hypertensive individuals with a focus on nutrition, and the need for further research. Awareness of dietary approach to stop hypertension (DASH) among health workers, obese and hypertensive individuals and it utilization in practice was low in PHC centers this is due to lack of registered dietitians’ nutritionists who are trained in MNT which is complicated by lack of ministerial funding of PHC facilities.

show abstract

“…Furthermore, WAT dysfunction due to metabolic disorders has a role in CKD development, progression, and co-morbidities. Specifically, the role of obesity-related adipose tissue dysfunction in the promotion and maintenance of kidney disease has been extensively reviewed and is outside of the scope of this mini-review [131][132][133] . Adipose tissue dysfunction in advanced kidney disease and obesity share similarities as most of the key cytokines, metabolites, and hormones that are dysregulated in uremia have been demonstrated to cause kidney injury in obesity models as well.…”

Section: Adipose Tissue Dysfunction and Ckd Progressionmentioning

confidence: 99%

Adipose tissue metabolic changes in chronic kidney disease

Serrano¹,

Shenoy²,

Cantarin³

2023

Immunometabolism

View full text Add to dashboard Cite

Adipose tissue is a complex organ whose functions go beyond being an energy reservoir to sustain proper body energy homeostasis. Functioning as an endocrine organ, the adipose tissue has an active role in the body’s metabolic balance regulation through several secreted factors generally termed as adipokines. Thus, adipose tissue dysregulation in chronic kidney disease (CKD) can have a deep impact in the pathophysiology of diseases associated with metabolic dysregulation including metabolic syndrome, insulin resistance (IR), atherosclerosis, and even cachexia. CKD is a progressive disorder linked to increased morbidity and mortality. Despite being characterized by renal function loss, CKD is accompanied by metabolic disturbances such as dyslipidemia, protein energy wasting, chronic low-grade inflammation, IR, and lipid redistribution. Thus far, the mechanisms by which these changes occur and the role of adipose tissue in CKD development and progression are unclear. Further understanding of how these factors develop could have implications for the management of CKD by helping identify pharmacological targets to improve CKD outcomes.

show abstract

Obesity-related kidney disease: Beyond hypertension and insulin-resistance

Cited by 31 publications

References 245 publications

Association between frailty and chronic kidney disease: Findings from CHARLS

Association between frailty and chronic kidney disease: Findings from CHARLS

Primary health care services for obesity and hypertension in sub-urban community: focus on nutrition

Adipose tissue metabolic changes in chronic kidney disease

Contact Info

Product

Resources

About